FDA approves 1st treatment for chronic lung disease

FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. Becker's Hospital Review